{"prompt": "['Is a congenital anomaly / birth defect in a neonate / infant born to a mother exposed to', 'study drug', \"Is a significant medical event in the investigator's judgment (e.g., may jeopardize the\", 'patient or may require medical / surgical intervention to prevent one of the outcomes', 'listed above)', 'The terms \"severe\" and \"serious\" are not synonymous. Severity refers to the intensity of an', 'AE (e.g., rated as mild, moderate, or severe, or according to NCI CTCAE v4.0; see Section', '5.3.3); the event itself may be of relatively minor medical significance (such as severe', 'headache without any further findings). Severity and seriousness need to be independently', 'assessed for each AE recorded on the eCRF.', 'Serious adverse events are required to be reported by the investigator to the Sponsor', 'immediately (i.e., no more than 24 hours after learning of the event; see Section 5.4.2 for', 'reporting instructions).', '5.2.3', 'Adverse Events of Special Interest (Immediately Reportable to the', 'Sponsor)', 'Adverse events of special interest are required to be reported by the investigator to the', 'Sponsor immediately (i.e., no more than 24 hours after learning of the event; see Section', '5.4.2 for reporting instructions). Adverse events of special interest for this study are as', 'follows:', 'An asymptomatic decline in LVEF that requires treatment or that leads to discontinuation', 'of study treatment', 'Cases of potential drug-induced liver injury that include an elevated ALT or AST in', \"combination with either an elevated bilirubin or clinical jaundice, as defined by Hy's Law\", '(see Section 5.3.5.6)', 'Suspected transmission of an infectious agent by the study drug, as defined below', 'Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible', 'spongiform encephalopathy), pathogenic or non-pathogenic, is considered an infectious', 'agent. A transmission of an infectious agent may be suspected from clinical symptoms', 'or laboratory findings that indicate an infection in a patient exposed to a medicinal', 'product. This term applies only when a contamination of the study drug is suspected.', '5.2.4', 'Selected Adverse Events', 'Additional data will be collected for the selected AEs described below.', '5.2.4.1', 'Heart Failure', 'Symptomatic LVSD (referred to as heart failure) should be reported as an SAE. If the', 'diagnosis is heart failure, it should be reported as such, and not as individual signs and', 'symptoms of heart failure. Heart failure should be graded according to both NCI CTCAE and', 'NYHA Class (see Appendix 7). Left ventricular ejection fraction results must also be reported.', 'Heart failure occurring during the study (including the Follow-up Period) must be reported', 'irrespective of causal relationship and followed until one of the following occurs: resolution or', 'improvement to baseline status, no further improvement can be expected, or death.', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '67 / Protocol MO40628, Version 12']['5.2.4.2', 'Asymptomatic Declines in Left Ventricular Ejection Fraction', 'Asymptomatic declines in LVEF should not be reported as AEs because LVEF data are', 'collected separately in the eCRF. Exceptions to this rule are as follows:', 'An asymptomatic decline in LVEF of 10 percentage-points from baseline to an LVEF', '< 50% must be reported as an AE with the term of \"ejection fraction decreased\", as per', 'NCI CTCAE v4.0 (see Appendix 7). In addition, a comment in the AEs comments field', 'should confirm that the event was asymptomatic.', 'An asymptomatic decline in LVEF requiring treatment or leading to discontinuation of', 'study treatment is an AE of special interest and must be reported in an expedited', 'manner (see Section 5.4.2). The event must be reported as an AE with the term of', '\"ejection fraction decreased\", as per NCI CTCAE v4.0 (see Appendix 7) and a comment', 'should be added to the AEs comments field confirming that the event was asymptomatic.', 'Table 1 summarizes the reporting conventions for LVSD and heart failure.', 'Table 1', 'Reporting Conventions for Left Ventricular Systolic', 'Dysfunction / Congestive Heart Failure', 'Observation', 'How to Report', 'Term to be Reported', 'Grading', 'Asymptomatic decline in', 'No additional', 'NA', 'NA', 'LVEF of < 10 percentage', 'reporting required;', 'points from baseline or to', 'LVEF results to be', 'an LVEF of 50%', 'reported on eCRF.', 'Asymptomatic decline in', 'AE [a] (eCRF AE', 'Ejection fraction', 'NCI CTCAE for', 'LVEF of 10 percentage', 'eForm)', 'decreased [a]', '\"ejection fraction', 'points from baseline to an', \"decreased'\", 'LVEF of < 50%', 'Asymptomatic decline in', 'AE (eCRF AE eForm)', 'Ejection fraction', 'NCI CTCAE for', 'LVEF requiring treatment or', 'and report as a non-', 'decreased [a]', '\"ejection fraction', 'leading to study treatment', 'serious AEs of', 'decreased\"', 'discontinuation', 'special interest on an', 'SAE form', 'Heart failure / CHF', 'AE (eCRF AE eForm)', '\"Heart failure\"', 'NCI CTCAE for', '(symptomatic LVSD) [b]', 'and SAE (SAE form)', '\"heart failure\" and', 'NYHA class', 'AE = adverse event; CHF = congestive heart failure; eCRF = electronic Case Report Form; eForm', '= electronic form; LVEF = left ventricular ejection fraction; LVSD = left ventricular systolic', 'dysfunction; NA = not applicable; NCI CTCAE = National Cancer Institute Common Terminology', 'Criteria for Adverse Events; NYHA = New York Heart Association; SAE = serious adverse event.', 'a. Report the status as asymptomatic and provide the LVEF value in the comments field as', 'appropriate.', 'b.', 'Any symptomatic LVSD event must be reported as \"heart failure.\"', '5.2.4.3', 'Administration-Related Reactions: Infusion-Related Reactions, Injection-', 'Related Reactions, and-Injection-Site Reactions and Infusion-Site', 'Reactions', 'Adverse events that occur during or within 24 hours after study drug administration and are', 'judged to be related to study drug infusion or injection should be captured as a specific', 'SC Fixed-Dose Combination of Pertuzumab and Trastuzumab - F. Hoffmann-La Roche Ltd', '68 / Protocol MO40628, Version 42']\n\n###\n\n", "completion": "END"}